The Nicklaus Children's Research Institute (NCRI) is a regional leader in providing pediatric clinical research services from the pharmaceutical, biotechnology, medical device industries, and from government agencies. The program provides comprehensive support for all types of clinical research studies, including Phase I to IV investigational drug studies. The NCRI supports interventional research studies along with providing various types of support to over 200 more observational research studies per year across nearly 30 subspecialties with a focus on cardiology, cardiovascular surgery, neurology, neurosurgery and oncology.
The Nicklaus Children's Research Institute is the largest provider of clinical research services for children of Latin origin in the southeastern United States. The NCRI is also a member of the distinguished Children's Oncology Group (COG), a national research collaborative providing the latest treatments for children with cancer.
Knowledgeable Research Team
Nicklaus Children's Research Institute employs knowledgeable clinical research coordinators with significant expertise and a track record in the field. Many of our research coordinators are certified by the Association of Clinical Research Professionals (ACRP) or the Society of Clinical Research Associates (SoCRA) and all are experienced in coordinating industry-sponsored clinical research projects.
Experienced Investigators
Nicklaus Children's Research Institute is home to investigators across nearly 30 subspecialties. They are experienced in multi-site clinical research investigations. Nicklaus Children's Hospital Investigators collaborate on research studies with investigators from other children's hospitals and academic institutions from all over the country.
Many investigators head research teams as principal investigators and lead sponsor-investigator studies and joint projects with academia. Nicklaus Children's Hospital investigators are knowledgeable and experienced in Phase I-IV clinical investigations in support of New Drug Applications (NDAs) and under Investigational Device Exemptions (IDEs). Their work also includes deployment of Humanitarian Use Devices (HUDs) and studies in support of orphan drug development.